[1]
|
Davies MJ. The pathophysiology of acute coronary syndromes[J]. Heart, 2000, 83(3):361-366. |
[2]
|
张艳容.动脉粥样硬化斑块显像研究进展[J].国外医学:放射医学核医学分册, 2004, 28(3):109-113.
|
[3]
|
Sadeghi MM, Glover DK, Lanza GM, et al. Imaging atherosclerosis and vulnerable plaque[J]. J Nucl Med, 2010, 51(Suppl 1):51S-65. |
[4]
|
Temma T, Saji H. Radiolabelled probes for imaging of atherosclerotic plaques[J]. Am J Nucl Med Mol Imaging, 2012, 2(4):432-447. |
[5]
|
Dachary-Prigent J, Freyssinet JM, Pasquet JM, et al. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation:a flow cytometry study showing a role for free sulfhydryl groups[J]. Blood, 1993, 81(10):2554-2565. |
[6]
|
Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V:a technique with potential for noninvasive imaging of vulnerable plaque[J]. Circulation, 2003, 108(25):3134-3139. |
[7]
|
Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis[J]. N Engl J Med, 2004, 305(14):1472-1473. |
[8]
|
Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with[18F]-fluorodeoxyglucose positron emission tomography[J]. Circulation, 2002, 105(23):2708-2711. |
[9]
|
Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation[J]. J Nucl Med, 2009, 50(4):563-568. |
[10]
|
Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation:evaluation by fluorodeoxyglucose positron emission tomography[J]. J Am Coll Cardiol, 2006, 48(9):1825-1831. |
[11]
|
Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction[J]. J Nucl Med, 2008, 49(8):1277-1282. |
[12]
|
Laitinen IE, Luoto P, Någren K, et al. Uptake of 11C-choline in mouse atherosclerotic plaques[J]. J Nucl Med, 2010, 51(5):798-802. |
[13]
|
Kato K, Schober O, Ikeda M, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT[J]. Eur J Nucl Med Mol Imaging, 2009, 36(10):1622-1628. |
[14]
|
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure, function, and biochemistry[J]. Circ Res, 2003, 92(8):827-839. |
[15]
|
Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina[J]. Circulation, 1995, 91(8):2125-2131. |
[16]
|
Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques:evidence for activation by proinflammatory mediators[J]. Circulation, 1999, 99(24):3103-3109. |
[17]
|
Ohshima S, Petrov A, Fujimoto S, et al. Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor[J]. J Nucl Med, 2009, 50(4):612-617. |
[18]
|
Langer HF, Haubner R, Pichler BJ, et al. Radionuclide imaging:a molecular key to the atherosclerotic plaque[J]. J Am Coll Cardiol, 2008, 52(1):1-12. |
[19]
|
Haider N, Hartung D, Fujimoto S, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis:molecular imaging facilitates understanding of pathogenesis[J]. J Nucl Cardiol, 2009, 16(5):753-762. |
[20]
|
Ohshima S, Fujimoto S, Petrov A, et al. Effect of an antimicrobial agent on atherosclerotic plaques:assessment of metalloproteinase activity by molecular imaging[J]. J Am Coll Cardiol, 2010, 55(12):1240-1249. |
[21]
|
Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis[J]. J Clin Invest, 1991, 88(6):1785-1792. |
[22]
|
Gerrity RG. The role of the monocyte in atherogenesis:I. Transition of blood-borne monocytes into foam cells in fatty lesions[J]. Am J Pathol, 1981, 103(2):181-190. |
[23]
|
Kugiyama K, Kerns SA, Morrisett JD, et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins[J]. Nature, 1990, 344(6262):160-162. |
[24]
|
Ishino S, Mukai T, Kuge Y, et al. Targeting of lectin like oxidized low-density lipoprotein receptor 1(LOX-1) with 99mTc-labeled anti-LOX-1 antibody:potential agent for imaging of vulnerable plaque[J]. J Nucl Med, 2008, 49(10):1677-1685. |
[25]
|
Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease[J]. Cardiovasc Res, 2002, 53(2):313-325. |
[26]
|
Ardissino D, Merlini PA, Bauer KA, et al. Thrombogenic potential of human coronary atherosclerotic plaques[J]. Blood, 2001, 98(9):2726-2729. |
[27]
|
Jeanpierre E, Le Tourneau T, Six I, et al. Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty:a potential role of tissue factor[J]. Circulation, 2003, 108(14):1740-1745. |
[28]
|
Temma T, Ogawa Y, Kuge Y, et al. Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model[J]. J Nucl Med, 2010, 51(12):1979-1986. |
[29]
|
Schmidt AM, Yan SD, Brett J, et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products[J]. J Clin Invest, 1993, 91(5):2155-2168. |
[30]
|
Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques:role of glycemic control[J]. Circulation, 2003, 108(9):1070-1077. |
[31]
|
Johnson LL, Tekabe Y, Kollaros M, et al. Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs[J]. EJNMMI Res, 2014, 4:26. |
[32]
|
Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture:angiogenesis as a source of intraplaque hemorrhage[J]. Arterioscler Thromb Vasc Biol, 2005, 25(10):2054-2061. |
[33]
|
Antonov AS, Kolodgie FD, Munn DH, et al. Regulation of macrophage foam cell formation by αvβ3 integrin:potential role in human atherosclerosis[J]. Am J Pathol, 2004, 165(1):247-258. |
[34]
|
Laitinen I, Saraste A, Weidl E, et al. Evaluation of αvβ3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice[J]. Circ Cardiovasc Imaging, 2009, 2(4):331-338. |
[35]
|
Beer AJ, Pelisek J, Heider P, et al. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis[J]. JACC Cardiovasc Imaging, 2014, 7(2):178-187. |
[36]
|
Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes[J]. J Am Coll Cardiol, 2007, 50(4):319-326. |
[37]
|
Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques[J]. Circulation, 2001, 103(8):1051-1056. |
[38]
|
oshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques:a prospective clinical trial[J]. Lancet, 2014, 383(9918):705-713. |